Long-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF

ISCHEMIA trial hailed as practice changing

The largest-ever RCT of initial invasive versus conservative management of stable ischemic heart disease makes waves.

*  *  *  

Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019

*  *  *  

DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics

Further analyses from the DAPA-HF trial showed dapagliflozin cut death and heart failure events in HFrEF patients with no diabetes.

The TWILIGHT of aspirin post-PCI for ACS?

Patients do better post-PCI for non-ST-elevation ACS with ticagrelor monotherapy

Weaknesses exposed in valsartan recall

ED visits for hypertension in month after the 2018 recall spiked 55%

*  *  *  

For more MDedge Podcasts, go to mdedge.com/podcasts

Email the show: [e-mail]

Interact with us on Twitter: @MDedgeTweets